These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35428548)

  • 41. Comparison of organ-at-risk sparing and plan robustness for spot-scanning proton therapy and volumetric modulated arc photon therapy in head-and-neck cancer.
    Barten DL; Tol JP; Dahele M; Slotman BJ; Verbakel WF
    Med Phys; 2015 Nov; 42(11):6589-98. PubMed ID: 26520750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Correlation between plan quality improvements and reduced acute dysphagia and xerostomia in the definitive treatment of oropharyngeal squamous cell carcinoma.
    Cui T; Ward MC; Joshi NP; Woody NM; Murray EJ; Potter J; Dorfmeyer AA; Greskovich JF; Koyfman SA; Xia P
    Head Neck; 2019 Apr; 41(4):1096-1103. PubMed ID: 30702180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A study on the impact of patient-related parameters in the ability to spare parotid glands by intensity-modulated radiotherapy for head and neck squamous cell carcinomas.
    Bandlamudi BP; Sharan K; Yathiraj PH; Singh A; Reddy A; Fernandes DJ; Srinivasa VM
    J Cancer Res Ther; 2018; 14(6):1220-1224. PubMed ID: 30488833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.
    Moreno AC; Frank SJ; Garden AS; Rosenthal DI; Fuller CD; Gunn GB; Reddy JP; Morrison WH; Williamson TD; Holliday EB; Phan J; Blanchard P
    Oral Oncol; 2019 Jan; 88():66-74. PubMed ID: 30616799
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of age on the outcome of patients treated with radiotherapy for mucoepidermoid carcinoma (MEC) of the salivary glands in the head and neck: A 15-year single-center experience.
    Akbaba S; Heusel A; Mock A; Held T; Lang K; Hoerner-Rieber J; Forster T; Katayama S; Kargus S; Rieken S; Plinkert P; Herfarth K; Debus J; Adeberg S
    Oral Oncol; 2019 Oct; 97():115-123. PubMed ID: 31494395
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
    Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
    Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
    Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
    Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer's ring: dosimetric analysis and clinical outcome.
    Bi XW; Li YX; Fang H; Jin J; Wang WH; Wang SL; Liu YP; Song YW; Ren H; Dai JR
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1086-93. PubMed ID: 24120822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intensity-Modulated Radiation Therapy Alone Versus Intensity-Modulated Radiation Therapy and Brachytherapy for Early-Stage Oropharyngeal Cancers: Results From a Randomized Controlled Trial.
    Budrukkar A; Murthy V; Kashid S; Swain M; Rangarajan V; Laskar SG; Kannan S; Kale S; Upreti R; Pai P; Pantvaidya G; Gupta T; Agarwal JP
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1541-1551. PubMed ID: 37660737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contribution of submandibular gland and swallowing structure sparing to post-radiation therapy PEG dependence in oropharynx cancer patients treated with split-neck IMRT technique.
    Gensheimer MF; Nyflot M; Laramore GE; Liao JJ; Parvathaneni U
    Radiat Oncol; 2016 Nov; 11(1):151. PubMed ID: 27846899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
    Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer.
    Rwigema JM; Langendijk JA; Paul van der Laan H; Lukens JN; Swisher-McClure SD; Lin A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):553-562. PubMed ID: 30625409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study.
    van der Laan HP; van de Water TA; van Herpt HE; Christianen ME; Bijl HP; Korevaar EW; Rasch CR; van 't Veld AA; van der Schaaf A; Schilstra C; Langendijk JA;
    Acta Oncol; 2013 Apr; 52(3):561-9. PubMed ID: 22708528
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Compensator-based intensity-modulated radiotherapy in head and neck cancer: our experience in achieving dosimetric parameters and their clinical correlation.
    Nangia S; Chufal KS; Arivazhagan V; Srinivas P; Tyagi A; Ghosh D
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):485-92. PubMed ID: 16909973
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
    Chao KS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Quantitative and qualitative investigations of salivary gland function in dependence on irradiation dose and volume for reduction of xerostomia in patients with head-and-neck cancer].
    Kuhnt T; Jirsak N; Müller AC; Pelz T; Gernhardt C; Schaller HG; Janich M; Gerlach R; Dunst J
    Strahlenther Onkol; 2005 Aug; 181(8):520-8. PubMed ID: 16044220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.